Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Biography

Lawrence Rubinstein received a Ph.D. in mathematical statistics from the Univ. of Maryland (1978). He has been in the NCI's Biometrics Research Program since 1985. He has published in a variety of areas relating to both clinical and pre-clinical studies. Dr. Rubinstein helped to define methods for determining the required sample size in phase 3 studies. He has been involved in developing new designs for phase 0 trials and phase 1 trials and defining appropriate designs for phase 2 trials. He was involved with establishing and updating the RECIST response criteria and participated in a 10-year review of phase 1 trial risks and benefits. He participated in the development of the in-vitro assay analysis tools used for the NCI human tumor cell line screen and was responsible for statistical analyses that determined the degree of correlation between in vitro and in vivo results, for that screen, and phase 2 clinical results. His current responsibilities involve primary statistical review and advising capacities on NCI/CTEP clinical studies and he helps design and analyze NCI/DCTD pre-clinical and early clinical studies. He also serves on data monitoring committees, national clinical trials steering committees, and statistical liaison responsibilities with national cancer clinical trials organizations. He is on the statistical editorial board of the Journal of the National Cancer Institute and the editorial board of Clinical Cancer Research.

Research Interests

Design, monitoring and analysis of clinical trials; pre-clinical drug screening and developmental clinical trials; gynecologic, gastrointestinal, and central nervous system cancer.
 

  • Updated:
Email